Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of IV FDY-5301 in anterior STEMI undergoing primary PCI
NL-OMON59028Phase 3Completed
- Sponsor
- Faraday Pharmaceuticals
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI) comparing FDY-5301 with Placebo (2 arms). Primary endpoint: Composite of cardiovascular mortality or heart failure event through Month 12. Started Aug 2022; status: completed.
02
Drugs
Sodium iodide
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NL-OMON59028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59028.